A Phase 2 interventional study of Ruxolitinib cream and Vehicle cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 6th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of HS (Hurley I or II) with the following:
Exclusion Criteria:
Concurrent conditions and history of other diseases:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
Drug: Ruxolitinib cream
Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
Drug: Vehicle cream
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Also known as: INCB018424 cream
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16
The mixed model repeated measure (MMRM) included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
Time frame: Baseline; Week 16
Percentage of Participants Achieving AN50, AN75, AN90, and AN100 at Week 16
AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, in AN count relative to Baseline.
Time frame: Baseline; Week 16
Change From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline
Pre-existing ANs at Baseline were defined as abscesses and/or inflammatory nodules present at Baseline. All new ANs identified during the study in an anatomical area that had pre-existing ANs at Baseline were counted. Any new ANs identified in an anatomical area that was initially free of ANs at Baseline were not counted. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
Time frame: Baseline; Week 16
Change From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16
The Skin Pain NRS is a daily participant-reported measure (24-hour recall) of the worst level of skin pain related to Hidradenitis Suppurativa. The participants rated the pain severity of their Hidradenitis Suppurativa by selecting a number from 0 (no pain) to 10 (worst imaginable pain) that best described their worst level of pain in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
Time frame: Baseline; Week 16
Change From Baseline in Itch NRS Score at Week 16
The Itch NRS is a daily participant-reported measure (24-hour recall) of the worst level of itch intensity related to Hidradenitis Suppurativa. The participants rated the itch severity of their Hidradenitis Suppurativa by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
Time frame: Baseline; Week 16
Percentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
HiSCR was defined as at least a 50% reduction in AN count with no increase in either abscess or draining fistula counts, relative to Baseline.
Time frame: Baseline; Week 16
Change From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16
The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. IHS4 score was calculated by the number of inflammatory nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). Scores: mild=0-3; moderate=4-10; severe ≥11. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
Time frame: Baseline; Week 16
Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: up to Week 16 plus 30 days
Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 16 plus 30 days
Number of Participants With Any TEAE in the Open-label Extension (OLE) Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: from Week 17 up to Week 32 plus 30 days
Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using CTCAE v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: from Week 17 up to Week 32 plus 30 days
| Milestone | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Open-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Started | 34 | 35 | 0 | 0 |
| Completed | 24 | 32 | 0 | 0 |
| Not completed | 10 | 3 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Presence of disease tunnel | 1 | 0 | 0 | 0 |
| Withdrew: Developed draining fistula | 0 | 1 | 0 | 0 |
| Milestone | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Open-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Started | 0 | 0 | 24 | 32 |
| Completed | 0 | 0 | 21 | 24 |
| Not completed | 0 | 0 | 3 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
The mixed model repeated measure (MMRM) included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
| ANs | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 | -3.61 ± 0.378 | -2.42 ± 0.336 |
AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, in AN count relative to Baseline.
| percentage of participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| AN50 | 79.2 | 56.3 |
| AN75 | 54.2 | 25.0 |
| AN90 | 20.8 | 12.5 |
| AN100 | 20.8 | 12.5 |
Pre-existing ANs at Baseline were defined as abscesses and/or inflammatory nodules present at Baseline. All new ANs identified during the study in an anatomical area that had pre-existing ANs at Baseline were counted. Any new ANs identified in an anatomical area that was initially free of ANs at Baseline were not counted. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
| ANs | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline to Week 16 in Total AN Count in Anatomical Areas With Pre-existing ANs at Baseline | -3.85 ± 0.362 | -3.17 ± 0.323 |
The Skin Pain NRS is a daily participant-reported measure (24-hour recall) of the worst level of skin pain related to Hidradenitis Suppurativa. The participants rated the pain severity of their Hidradenitis Suppurativa by selecting a number from 0 (no pain) to 10 (worst imaginable pain) that best described their worst level of pain in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
| scores on a scale | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline in Skin Pain Numeric Rating Scale (NRS) Score at Week 16 | -1.90 ± 0.532 | -2.09 ± 0.497 |
The Itch NRS is a daily participant-reported measure (24-hour recall) of the worst level of itch intensity related to Hidradenitis Suppurativa. The participants rated the itch severity of their Hidradenitis Suppurativa by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
| scores on a scale | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline in Itch NRS Score at Week 16 | -1.45 ± 0.538 | -2.39 ± 0.493 |
HiSCR was defined as at least a 50% reduction in AN count with no increase in either abscess or draining fistula counts, relative to Baseline.
| percentage of participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Percentage of Participants Who Achieve Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 79.2 | 50.0 |
The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. IHS4 score was calculated by the number of inflammatory nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). Scores: mild=0-3; moderate=4-10; severe ≥11. The MMRM included the fixed effects of the treatment group (ruxolitinib 1.5% and vehicle cream), stratification factor (Baseline AN count of ≥3 to 4 or ≥5 to 10), visit, and visit-by-treatment interaction. Change from Baseline was calculated as the Week 16 value minus the Baseline value.
| scores on a scale | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Change From Baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16 | -3.58 ± 0.505 | -2.76 ± 0.459 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period | 13 | 15 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period | 0 | 2 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | OLE Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Number of Participants With Any TEAE in the Open-label Extension (OLE) Period | 8 | 15 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. The severity of AEs was assessed using CTCAE v5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | OLE Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period | 0 | 3 |
Collected over up to Week 32 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream BID | 0/35 (0%) | 1/35 (2.9%) | 2/35 (5.7%) |
| Ruxolitinib 1.5% Cream BID | 0/66 (0%) | 2/66 (3%) | 5/66 (7.6%) |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/35 | 0/66 |
| Acute kidney injuryRenal and urinary disorders | 0/35 | 1/66 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/35 | 1/66 |
| Crohn's diseaseGastrointestinal disorders | 0/35 | 1/66 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/35 | 1/66 |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/35 | 5/66 |
| NauseaGastrointestinal disorders | 2/35 | 0/66 |
| Age, Continuous(years) | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 32.0 ± 9.83 | 31.3 ± 9.84 | 31.7 ± 9.76 |
| Sex: Female, Male(Participants) | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Female | 29 | 33 | 62 |
| Male | 5 | 2 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 1 | 8 |
| Not Hispanic or Latino | 27 | 34 | 61 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID | Total |
|---|---|---|---|
| White/Caucasian | 19 | 12 | 31 |
| Black/African-American | 11 | 18 | 29 |
| Asian | 0 | 2 | 2 |
| Unknown | 1 | 0 | 1 |
| Mixed Race: Black and White | 1 | 0 | 1 |
| White and American Indian/Alaska Native | 2 | 0 | 2 |
| Half White, Half Asian | 0 | 1 | 1 |
| Metis, White | 0 | 1 | 1 |
| North African | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Dec 2022 to primary completion in Oct 2023, 10 months.
Results were first posted in Nov 2024, 1 year after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 10 months is below that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib